microdosing glp-1 receptor agonists GLP-1s: Does It Work? Risks and Benefits Injectable GLP-1 Receptor Agonists -

This clinical evidence base has legitimized GLP-1 compounds as mainstream precision medicine rather than niche diabetes treatment

doi: 10.1111/dom.15896 78 HuangYNLiaoWLHuangJYLinYJYangSFHuangCCet al

Jin T, Weng J

Fixed-ratio combinations Xultophy (insulin degludec + liraglutide) represents the current state of combined therapy

Tier 2 is less well-validated therapies and includes agents from tier 1 with the addition of pioglitazone and GLP-1 agonists

These medications should be avoided during pregnancy and breastfeeding, and women of reproductive potential should discontinue treatment at least 2 months before a planned pregnancy